ECSP077395A - CARBAMATE COMPOUND FOR USE IN THE TREATMENT OF NEURODEGENERATIVE PADCIMIENTS - Google Patents
CARBAMATE COMPOUND FOR USE IN THE TREATMENT OF NEURODEGENERATIVE PADCIMIENTSInfo
- Publication number
- ECSP077395A ECSP077395A EC2007007395A ECSP077395A ECSP077395A EC SP077395 A ECSP077395 A EC SP077395A EC 2007007395 A EC2007007395 A EC 2007007395A EC SP077395 A ECSP077395 A EC SP077395A EC SP077395 A ECSP077395 A EC SP077395A
- Authority
- EC
- Ecuador
- Prior art keywords
- formula
- group
- phenyl
- alkyl
- padcimients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
Abstract
La presente invención está dirigida a métodos para proveer neuroprotección que comprende la administración a un sujeto que lo necesita de una cantidad terapéuticamente efectiva de un compuesto seleccionado del grupo que consiste de la Fórmula (I) y la Fórmula (II) ó una sal o éster farmacéuticamente aceptable de las mismas; la Fórmula (I), Fórmula (II), en donde el fenilo es sustituido en X con de uno a cinco átomos de halógeno seleccionados del grupo que consiste en flúor, cloro, bromo y yodo; y X1, X2, X3, X4, X5 y X6 son seleccionados del grupo que consiste en hidrógeno y alquilo de C1-C4, en donde el alquilo de C1-C4 es sustituido opcionalmente con fenilo (en donde el fenilo es opcionalmente sustituido con sustituyentes seleccionados independientemente del grupo que consiste en halógeno, alquilo de C1-C4, alcoxi de C1-C4, amino, nitro y ciano).The present invention is directed to methods for providing neuroprotection comprising administration to a subject in need of a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II) or a salt or ester pharmaceutically acceptable thereof; Formula (I), Formula (II), wherein the phenyl is substituted in X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and X1, X2, X3, X4, X5 and X6 are selected from the group consisting of hydrogen and C1-C4 alkyl, wherein the C1-C4 alkyl is optionally substituted with phenyl (wherein the phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61940204P | 2004-10-15 | 2004-10-15 | |
| US69840305P | 2005-07-12 | 2005-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP077395A true ECSP077395A (en) | 2007-05-30 |
Family
ID=35840528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2007007395A ECSP077395A (en) | 2004-10-15 | 2007-04-13 | CARBAMATE COMPOUND FOR USE IN THE TREATMENT OF NEURODEGENERATIVE PADCIMIENTS |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1802294A1 (en) |
| JP (1) | JP2008516961A (en) |
| KR (3) | KR20090130175A (en) |
| AU (1) | AU2005295787A1 (en) |
| BR (1) | BRPI0516112A (en) |
| CA (1) | CA2584854A1 (en) |
| EA (1) | EA200700871A1 (en) |
| EC (1) | ECSP077395A (en) |
| IL (1) | IL182432A0 (en) |
| MX (1) | MX2007004491A (en) |
| NI (1) | NI200700094A (en) |
| NO (1) | NO20072444L (en) |
| SG (1) | SG142306A1 (en) |
| WO (1) | WO2006044472A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2783699C (en) | 2009-12-08 | 2019-01-15 | Case Western Reserve University | Primary amine compounds for treating ocular disorders |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| KR20190081385A (en) | 2017-12-29 | 2019-07-09 | 강원대학교산학협력단 | Composition for preventing the ischemia stroke disease containing oxcarbazepine |
| BR112023003473A2 (en) * | 2020-08-31 | 2023-04-11 | Bio Pharm Solutions Co Ltd | ALKYL PHENYL CARBAMATE COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE |
| EP4211125A1 (en) | 2020-09-10 | 2023-07-19 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| US20010034365A1 (en) * | 1996-01-16 | 2001-10-25 | Choi Yong Moon | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| DE60016602T2 (en) * | 1999-08-20 | 2005-11-03 | Ortho-Mcneil Pharmaceutical, Inc. | COMPOSITION CONTAINING A TRAMADOL AND AN ANTICONVULSIVE MEDICAMENT |
| KR100910928B1 (en) * | 2001-02-27 | 2009-08-06 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | A pharmaceutical composition comprising carbamate compounds for use in preventing or treating neurodegenerative disorders |
| US20060194873A1 (en) * | 2004-09-16 | 2006-08-31 | Choi Yong M | Methods of treating epileptogenesis and epilepsy |
-
2005
- 2005-10-14 EP EP05810159A patent/EP1802294A1/en not_active Withdrawn
- 2005-10-14 WO PCT/US2005/036695 patent/WO2006044472A1/en active Application Filing
- 2005-10-14 KR KR1020097019737A patent/KR20090130175A/en active Search and Examination
- 2005-10-14 NI NI200700094A patent/NI200700094A/en unknown
- 2005-10-14 EA EA200700871A patent/EA200700871A1/en unknown
- 2005-10-14 MX MX2007004491A patent/MX2007004491A/en unknown
- 2005-10-14 BR BRPI0516112-6A patent/BRPI0516112A/en not_active IP Right Cessation
- 2005-10-14 AU AU2005295787A patent/AU2005295787A1/en not_active Abandoned
- 2005-10-14 SG SG200802877-1A patent/SG142306A1/en unknown
- 2005-10-14 CA CA002584854A patent/CA2584854A1/en not_active Abandoned
- 2005-10-14 JP JP2007536843A patent/JP2008516961A/en active Pending
- 2005-10-14 KR KR1020077010744A patent/KR20070085309A/en active Application Filing
- 2005-10-14 KR KR1020117007395A patent/KR20110049901A/en not_active Application Discontinuation
-
2007
- 2007-04-10 IL IL182432A patent/IL182432A0/en unknown
- 2007-04-13 EC EC2007007395A patent/ECSP077395A/en unknown
- 2007-05-11 NO NO20072444A patent/NO20072444L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL182432A0 (en) | 2007-09-20 |
| JP2008516961A (en) | 2008-05-22 |
| MX2007004491A (en) | 2007-08-08 |
| KR20090130175A (en) | 2009-12-18 |
| NI200700094A (en) | 2008-02-11 |
| NO20072444L (en) | 2007-06-14 |
| EA200700871A1 (en) | 2007-10-26 |
| SG142306A1 (en) | 2008-05-28 |
| KR20110049901A (en) | 2011-05-12 |
| EP1802294A1 (en) | 2007-07-04 |
| WO2006044472A1 (en) | 2006-04-27 |
| KR20070085309A (en) | 2007-08-27 |
| BRPI0516112A (en) | 2008-08-26 |
| CA2584854A1 (en) | 2006-04-27 |
| AU2005295787A1 (en) | 2006-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088179A (en) | CARBAMATE COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | |
| NO20071921L (en) | Methods for treating epileptogenesis and epilepsy | |
| ECSP088172A (en) | METHODS TO TREAT EPILEPTOGENESIS | |
| CO6180427A2 (en) | TREATMENT OF THE GENERALIZED DISORDERS OF DEVELOPMENT | |
| ECSP077395A (en) | CARBAMATE COMPOUND FOR USE IN THE TREATMENT OF NEURODEGENERATIVE PADCIMIENTS | |
| AR054524A1 (en) | METHODS AND DOSAGE FORMS TO REDUCE THE SIDE EFFECTS OF CARBAMATE COMPOUNDS | |
| EA200800422A1 (en) | METHODS OF TREATMENT OF DISEASES DETERMINED BY CHEMICALS | |
| EA200701536A1 (en) | WAYS OF QT INTERVAL CONTROL | |
| AR033426A1 (en) | USE OF CARBAMATE COMPOUNDS IN THE PREVENTION OR TREATMENT OF MOVEMENT DISORDERS | |
| CO6180505A2 (en) | METHODS FOR THE TREATMENT OF COCLEAR AND VESTIBULAR DISORDERS | |
| DK1408953T3 (en) | Carbamate compounds for use in the prevention or treatment of bipolar disorder | |
| CO6160292A2 (en) | METHODS OF TREATMENT OF DISTURBING BEHAVIOR DISORDERS 877 | |
| TW200701978A (en) | Methods of treating epileptogenesis and epilepsy | |
| CY1110672T1 (en) | USE OF 2- FENYL-1,2-ETHANODIOL- (DI) CARBAMIC FOR SELECTION THERAPY | |
| AR035757A1 (en) | USE OF CARBAMATES FOR THE MANUFACTURE OF MEDICINES TO PREVENT OR TREAT A BIPOLAR DISORDER | |
| PE20060559A1 (en) | CARBAMATE-DERIVED COMPOUNDS FOR THE TREATMENT OF SUBSTANCE-RELATED DISORDERS | |
| CR9766A (en) | METHODS FOR THE TREATMENT OF SUBSTANCE-RELATED DISORDERS | |
| MY136733A (en) | Carbamate compounds for use in preventing or treating psychotic disorders |